A monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants
Authors: Hong, Hsiang; Wu, Madeline; Chong, Sue; Yu, Jian; Mellis, Ian A; Huang, Chien-Yu; Wang, Qian; Huang, Yaoxing; Guo, Yicheng; Ho, David D
Source journal: Cell reports (2026-11-19)
DOI: 10.1016/j.celrep.2026.118355
Abstract
SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibodies (mAbs) were derived from ancestral or early Omicron strains and have lost activity against recent variants, limiting their ability to resolve the antigenic effects of mutations arising in emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune mice with the KP.3.1.1 spike, and isolated and characterized 11 human neutralizing antibodies targeting diverse epitopes of evolved variants. We then integrated these antibodies with characterized mAbs to establish a toolbox for profiling antigenic evolution among emerging variants. Application of this panel to emerging variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.
Related topics
Related open access articles
- CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH COLORECTAL CANCER AND COVID-19 COINFECTION - CASE REPORT
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- The use of non-invasive ventilation (NIV) in the treatment of patients with COVID-19
- Application of Nanotechnology in Treatment of COVID-19
- Nano Platforms in Combatting COVID-19: Unveiling Antiviral Strategies and Challenges
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.